慢加急性乙型肝炎肝衰竭患者血清自噬相关蛋白水平及其临床意义探讨*

doi:10.3969/j.issn.1672-5069.2021.05.029

Abstract

Abstract: Objective The aim of this study was to explore the clinical significance of serum p62, microtubule-associated protein 1 light chain 3-II (LC3-II) and Beclin1 in patients with hepatitis B virus infection-induced acute-on-chronic liver failure (HBV-ACLF). Methods Sixty patients with HBV-ACLF and 65 subjects who underwent physical examination in our hospital during the same period were recruited in this study between September 2018 and September 2020. The scores of model for end-stage liver disease (MELD) were calculated. Serum 62, Beclin1 and LC3-II levels were detected by ELISA. The predictive efficacy of serum p62, Beclin1 and LC3-II as well as MELD for prognosis of patients with HBV-ACLF was evaluated by area under the receiver operating characteristic curves (AUROC). Results At admission, serum LC3-Ⅱ and Beclin1 levels in patients with HBV-ACLF were (66.8±13.5)ng/mL and (11.7±3.6)ng/mL, both significantly higher than [(35.8±6.2)ng/mL and (8.2±2.9)ng/mL, respectively, P＜0.05], while serum p62 level was (2.5±0.9)ng/mL, significantly lower than [(4.5±1.6)ng/mL, P＜0.05] in the control; at day 90, 18 patients(30.0%)died; serum LC3-Ⅱ, Beclin1 levels and MELD score in dead patients at presentation were (76.25±12.1)ng/mL, (10.9±3.2)ng/mL and (20.1±3.3), all significantly higher than [(62.8±10.2)ng/mL,(13.4±3.5)ng/mL and (16.7±4.6), respectively, P＜0.05], while serum p62 level was (1.7±0.6)ng/mL, much lower than in the survivals; the ROC analysis showed that serum p62＜2.2 ng/mL, LC3-Ⅱ＞70.3 ng/mL and Beclin1＞12.6 ng/mL were set as the cut-off-value, the AUC were 0.856, 0.820 and 0.765 in predicting the poor prognosis of patients with HBV-ACLF, and the AUC of the three combination was 0.910, similar to 0.917 by MELD score when greater than 18.3 of it was set as the cut-off-value. Conclusion Serum p62, LC3-II and Beclin1 levels might be monitored and applied to predict the prognosis of patients with HBV-ACLF.

Key words: Acute-on-chronic liver failure, Microtubule-associated protein 1 light chain 3-II, p62, Beclin1, Prognosis, Diagnostic trial

Huang Shuangxiang, Yao Chaoguang, Lan Jing, et al. Clinical significance of serum autophagy-related proteins in patients with hepatitis B virus-induced acute on chronic liver failure[J]. Journal of Practical Hepatology, 2021, 24(5): 721-724.

References

[1]Wu T, Li J, Shao L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut, 2018,67(12):2181-2191.
[2]Liu L, Lan Q, Lin L, et al. Gamma-glutamyl transpeptidase-to-platelet ratio predicts the prognosis in HBV-associated acute-on-chronic liver failure. Clin Chim Acta, 2018,476:92-97.
[3]赵洁,李力,李秀惠, 等.乙型肝炎病毒相关慢加急性肝衰竭患者短期预后模型的建立及预测价值研究.中华危重病急救医学, 2020,32(8):988-993.
[4]Liu L, Lu J, Ye C, et al. Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure. Biomed Rep, 2018,8(2):166-171.
[5]Yan Q, Wang L, Lai L, et al. Next generation sequencing reveals novel alterations in B-cell heavy chain receptor repertoires associated with acute-on-chronic liver failure. Int J Mol Med, 2019,43(1):243-255.
[6]Lin S, Zhang K, Zhang J, et al. Long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure: An observational cohort study. Liver Int, 2019,39(5):854-860.
[7]王培,张青,李颍, 等.基于红细胞分布宽度和中性粒细胞/淋巴细胞比值建立慢加急性乙型肝炎肝衰竭患者短期预后预测模型价值研究.实用肝脏病杂志, 2020,23(5):682-686.
[8]Yao J, Li S, Zhou L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure. J Clin Apher, 2019,34(4):392-398.
[9]Tahrir FG, Shanmughapriya S, Ahooyi TM, et al. Dysregulation of mitochondrial bioenergetics and quality control by HIV-1 Tat in cardiomyocytes. J Cell Physiol, 2018,233(2):748-758.
[10] 王晨宇,刘超,郑蔚.Klotho及自噬相关蛋白微管相关蛋白1轻链3在胃癌中的水平及意义.中华实验外科杂志, 2016,33(2):321-323.
[11] 中华医学会感染病学分会肝衰竭与人工肝学组;中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22(2):164-171.
[12] Xie Z, Violetta L, Chen E, et al. A prognostic model for hepatitis B acute-on-chronic liver failure patients treated using a plasma exchange-centered liver support system. J Clin Apher, 2020,35(2):94-103.
[13] Shen G, Sun S, Huang J, et al. Dynamicchanges of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure. Hepatol Int, 2020,14(1):47-56.
[14] Yang L, Wu T, Li J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: A case-control matched analysis. Hepatol Res, 2020,50(6):656-670.
[15] Spagnuolo MS, Bergamo P, Crescenzo R, et al. Brain Nrf2 pathway, autophagy, and synaptic function proteins are modulated by a short-term fructose feeding in young and adult rats. Nutr Neurosci, 2020,23(4):309-320.
[16] 吴云辉,谢新生,邓敏.血清M30和M65水平变化对乙型肝炎病毒相关慢加急性肝衰竭患者人工肝治疗短期预后的预测价值.中华传染病杂志, 2019,37(11):661-666.
[17] Cj P, Hv E, Vijayakurup V, et al. High LC3/Beclin expression correlates with poor survival in glioma: a definitive role for autophagy as evidenced by in vitro autophagic flux. Pathol Oncol Res, 2019,25(1):137-148.
[18] Zhang Y, Wang H, Li F, et al. Inhibitory effects of Dulcitol on rat C6 glioma by regulating autophagy pathway. Nat Prod Res, 2020,34(10):1437-1441.
[19] Kwon I, Jang Y, Cho JY, et al. Long-term resistance exercise-induced muscular hypertrophy is associated with autophagy modulation in rats. J Physiol Sci, 2018,68(3):269-280.
[20] Li W, Li S, Li Y, et al. Immunofluorescence staining protocols for major autophagy proteins including LC3, P62, and ULK1 in mammalian cells in response to normoxia and hypoxia. Methods Mol Biol, 2019,1854:175-185.
[21] Yuan Y, Pan SS, Shen YJ. Cardioprotection of exercise preconditioning involving heat shock protein 70 and concurrent autophagy: a potential chaperone-assisted selective macroautophagy effect. J Physiol Sci, 2018,68(1):55-67.

Clinical significance of serum autophagy-related proteins in patients with hepatitis B virus-induced acute on chronic liver failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Hua Qi, Chen Qi, You Lan. Clinical feature of 142 patients with anti-tuberculosis agents-induced DILI [J]. Journal of Practical Hepatology, 2021, 24(6): 843-846.
[2]	Liu Jiqing, Yu Guoying, Yang Shengsen, et al. Short-term prognosis of patients with acute on chronic liver failure and invasive fungal infection by four prognostic scoring systems [J]. Journal of Practical Hepatology, 2021, 24(6): 851-854.
[3]	Dong Jinling, Li Lu, Chen Yu. Discrimination of slow continuous acute-on-chronic liver failure and chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(5): 611-612.
[4]	Guan Haiyan, Yang Wenbin. Clinical features and prognosis of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(5): 713-716.
[5]	Chen Dandan, Long Zhida, Huang Shundong, et al. Risk factors of infection and acute kidney injury in patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2021, 24(5): 717-720.
[6]	Song Xue, Xi Zihan, Li Ting, et al. Clinical implication of serum CXCL9 and IFN-γ levels in patients with intrahepatic cholangiocarcinoma [J]. Journal of Practical Hepatology, 2021, 24(5): 741-744.
[7]	Li Bianli, Xu Lihong. Differential diagnosis of drug-induced liver injury, drug-induced autoimmune hepatitis and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 460-463.
[8]	Lu Xiaolong, Xie Chunbao. Implication of IL-6 gene polymorphism in short-term prognosis of patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(4): 516-519.
[9]	Li Zhenkun , He Lyufen, Li Huan, et al. Clinical features and influencing factors of invasive fungal infections in patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2021, 24(4): 520-523.
[10]	Zhang Bing, Chen Ruihong, Yang Wei, et al. Application of serum HSP90α and PIVKA-II levels in prognosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(4): 548-551.
[11]	Wang Tingting, Xin Yang, Wang Nana. Expression of CBX7 and PERK incancerous tissues in patients with hepatocellular carcinoma and its implication of prognosis after hepatectomy [J]. Journal of Practical Hepatology, 2021, 24(4): 552-555.
[12]	Yu Zhe, Luo Jing, Yang Yongping. Peripheral blood mononuclear cell GPSM2 levels might be a new marker for prognosis of patients with hepatocellular carcinoma stage III [J]. Journal of Practical Hepatology, 2021, 24(4): 556-560.
[13]	Yu Tao, Li Kuiwu, Yao Lin, et al. Implication of ubiquitinase E2T expression in cancerous tissues in patients with gallbladder cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 593-596.
[14]	Wang Mengyu, Yang Ruixu, Fan Jiangao. Clinical feature and outcomes of patients with metabolic associated fatty liver diseases [J]. Journal of Practical Hepatology, 2021, 24(3): 308-311.
[15]	Lin Liekun, Lu Chunsheng, Zhou Yingsheng, et al. Changes of histone deacetylase mRNA levels after histone acetylation inhibitor management in liver tissue of mice with acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2021, 24(3): 327-330.